Hostname: page-component-6766d58669-vgfm9 Total loading time: 0 Render date: 2026-05-21T23:00:31.952Z Has data issue: false hasContentIssue false
  • English
  • Français

Cholesterol hydroxylation products confer resistance to anthracyclines in Triple Negative Breast Cancer

Published online by Cambridge University Press:  26 January 2018

S.A. Hutchinson ,
D.A. Kane ,
H. Røberg-Larsen ,
K. Vaghela  and
J.L. Thorne
S.A. Hutchinson
Affiliation:
School of Food Science and Nutrition, University of Leeds, LS2 9JT
D.A. Kane
Affiliation:
School of Food Science and Nutrition, University of Leeds, LS2 9JT
H. Røberg-Larsen
Affiliation:
Department of Chemistry, University of Oslo, Norway and School of Medicine.
K. Vaghela
Affiliation:
School of Food Science and Nutrition, University of Leeds, LS2 9JT
J.L. Thorne
Affiliation:
School of Food Science and Nutrition, University of Leeds, LS2 9JT
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

For Triple Negative Breast Cancer (TNBC) patients, treatment commonly consists of surgery, local radiotherapy and systemic chemotherapy. Prognosis following metastatic relapse (which indicates failure of systemic chemotherapy) is poor as fewer than 1 in 10 of these patients survive longer than two-years. The 2017 WCRF Breast Cancer Continuous Update Project( 1 ) reported convincing risk factors for BCa that are common comorbidities with hypercholesterolemia (e.g. obesity, waist-hip-ratio). At the nutrient-gene interaction level this is intriguing because cholesterol is hydroxylated into oxysterols (OHCs), a group of potent signaling molecules that drive TNBC metastasis through the Liver X Receptor (LXR)( Reference Nelson 2 ) and are elevated in serum at metastatic relapse( Reference Dalenc 3 ). Dietary( Reference Chlebowski 4 ) and pharmacological( Reference Liu, Yi, Guan, Zeng and Ma 5 ) interventions that lower circulating concentrations of cholesterol and oxysterols, also improve BCa disease free survival. Dietary phytosterols in particular not only reduce circulating cholesterol and OHC concentrations, but their structural similarity to OHCs suggests they are modulators of the LXR-OHC axis. The aims of this study were to evaluate i) if the LXR-OHC axis confers chemoresistance in BCa, and ii) if phytosterols antagonise this pathway.

Pretreatment of TNBC cells in culture with LXR specific ligands led to altered intra-cellular retention of the fluorescent anthracycline, epirubicin (Fig 1) and altered epirubicin induced cell death in colony forming assays (Fig 2). To test if phytosterols could impair the oxysterol-LXR axis, stable LXR-reporter cell lines were generated. Transactivation of LXR was inhibited in the presence of Sitosterol or the synthetic LXR antagonist GSK2033 (Fig 3). Sitosterol treatment was also found to significantly impair TNBC mammosphere formation (Fig 4).

Fig. 1.

Modulating LXR activity with agonist or antagonist enhances the cell's ability to efflux epirubicin (100uM).

Fig. 2.

Colony Forming Assay show LXR activity modifies cellular survival in response to epirubucin.

Fig. 3.

Transactivation of LXR by OHC is impaired by synthetic antagonist and Sitosterol (SIT).

Fig. 4.

Mammopshere formation is impaired by Sitosterol. All data show mean of 2-5 independent biological replicates. Student's t-test or ANOVA were used to assess statistical significance.

Targeting LXR transcriptional capacity with highly specific ligands led to changes in retention of epirubicin and tumour cell survival. Phytosterol treatment impaired the ability of an endogenous OHC to transactivate LXR and for TNBC cells to form mammospheres. We have now begun measuring OHC and phytosterol content of primary tumours to evaluate if intra-tumoural concentrations of OHCs are sufficient to transactivate LXR and if they are functional biomarkers of tumour relapse. Giventhe ease with which phytosteorls could be adopted into therapeutic nutritional advice we propose they should be evaluated as modifiers of the chemoresponse in TNBC patients, particularly those who present with elevated circulating cholesterol.

References

1 WCRF/AICR. Continuous Update Project Report: Diet, Nutrition, Physical Actvity and Cancer 2017.Google Scholar
2 Nelson, ER et al. (2013) Science 342, 1094–8.CrossRefGoogle Scholar
3 Dalenc, F et al. (2016) J Steroid Biochem Mol Biol 169, 210–8.CrossRefGoogle Scholar
4 Chlebowski, RT et al. (2006) J Natl Cancer Inst 98, 1767–76.CrossRefGoogle Scholar
5 Liu, B, Yi, Z, Guan, X, Zeng, YX & Ma, F (2017) Breast Cancer Res Treat 164, 1–11.CrossRefGoogle Scholar
Figure 0

Fig. 1. Modulating LXR activity with agonist or antagonist enhances the cell's ability to efflux epirubicin (100uM).

Figure 1

Fig. 2. Colony Forming Assay show LXR activity modifies cellular survival in response to epirubucin.

Figure 2

Fig. 3. Transactivation of LXR by OHC is impaired by synthetic antagonist and Sitosterol (SIT).

Figure 3

Fig. 4. Mammopshere formation is impaired by Sitosterol. All data show mean of 2-5 independent biological replicates. Student's t-test or ANOVA were used to assess statistical significance.